

UCLH NHS Foundation Trust


Update on performance and management of Covid-19 for Islington HSC

Flo Panel-Coates, Chief Nurse (and executive EPRR lead)
Alex Gregg, Head of Performance

Performance against key targets

- Covid-19
- Impact on waiting for treatment
- Cancer waiting times
- Waiting times in our emergency department
- Strategic developments
- Financial position

Covid-19: an unprecedented demand for beds



- There are normally 62 intensive care beds at UCLH. The trust created another 61 beds outside the normal intensive care area.
- At the peak of the second wave we had 118 patients (85 were Covid) in ICU
- We opened a further 34 beds outside ICU where non-invasive ventilation (CPAP) could be provided.
- In the first wave up to 170 beds were occupied by Covid patients. In the second wave over 250 beds were occupied.
- We have had over 1,500 Covid admissions.
- In the first wave (up to end August) there were 186 deaths. In the second wave there have been 211 to date.

Covid-19: an amazing clinical and operational response




COVID Reporting - UCLH Daily SITREP

Snapshot Dtm | 21 Feb 2021 08:12:00
Last Refresh Dtm | 21 Feb 2021 09:21:01


ED Area Type	Admitted from ED	Discharged from ED	Total
UCH ED Majors	42	90	132
UCH ED UTC	4	93	97
Total	46	183	229



	COVID Positive	Other
Admissions - Last 24 Hours	6	82
Discharges - Last 24 Hours	11	85
Deaths - Last 24 Hours	1	1
COVID Deaths - All	392	0



Capacity Type	COVID+	Other	Total	Infectious
HDU	11	16	27	6
ICU Mech Vent	33	13	46	22
ICU Neonatal	1	25	26	0
ICU NIV	6	9	15	1
ICU Non Vent	5	15	20	4
Ward Bay Bed	56	401	457	21
Ward Side Room	27	163	190	15
Total	139	642	781	69



Ward Name	COVID+	Infectious
UCH T07 CV SURGE	25	15
UCH T09 NORTH (T09N)	19	14
NHNN C4 NUFFIELD WARD	9	8
UCH T08 NORTH (T08N)	14	8
UCH T03 INTENSIVE CARE	10	7
UCH T09 SOUTH (T09S)	17	6
UCH P03 CV	6	4
EGA ED3 MCU	2	1
MCC H02 AMBULATORY	1	1
NHNN C1 SURGICAL ITU	2	1
OFF UCLH@HOME	3	1
UCH T01 ENHANCED CARE	2	1
UCH T08 SOUTH (T08S)	1	1
Total	139	69


Professional Group	COVID+	Isolating	COVID Potential	Sick Other	Total
Add Prof Scientific and Tech...	0	8	3	5	16
Additional Clinical Services	2	32	8	50	92
Administrative and Clerical	4	3	1	36	44
Allied Health Professionals	0	3	1	9	13
Estates and Ancillary	0	13	0	4	17
Healthcare Scientists	0	0	0	0	0
Medical and Dental	1	4	3	14	22
Nursing and Midwifery Regis...	3	91	10	103	207
Total	10	154	26	221	411

Site	Oxygen Usage (L/min)	Change in % Prev Day	% of Total Capacity
NHNN	628	1.80%	21.00%
UCH	615	0.60%	12.00%


Covid-19: contributing to knowledge about Covid-19

- **CPAP device:** A breathing aid that can help keep Covid-19 patients out of intensive care was approved for use in the NHS in March. This was a UCL/UCLH/Mercedes-AMG device.
- **Quick to open clinical trials:** by 7 April we had opened 9 clinical trials into Covid-19 and by 1 May we had opened 24 clinical trials in total.
- **UCLH a main test site for the Oxford vaccine:** In May we started trialling the Oxford vaccine
- **Key partner in the post-hospital Covid study:** In July we launched the PHOSP-COVID study, the largest study in the world to understand and improve the health of survivors after hospitalisation from COVID-19
- In July, a new UCL and UCLH-led study found that **neurological complications of COVID-19** can include delirium, brain inflammation, stroke and nerve damage.
- **UCLH study pinpoints loss of smell as key symptom:** A UCL and UCLH study found in October that acute loss of sense of smell should be considered as a criterion for self-isolation, testing and contact tracing for Covid-19.
- In October, UCLH announced it was taking part in a first-of-its kind clinical trial led by scientists at UCL to evaluate the use of **'real time' viral genomic data** to reduce the spread of COVID-19 within hospitals.
- **UCLH doses first patient in the world in monoclonal antibody trial:** On Christmas Day we announced the opening of the new Vaccine Research Centre with two new clinical trials looking at whether monoclonal antibodies could work as a treatment for Covid-19



Covid-19: contributing to the vaccination effort



- UCLH has vaccinated 30,000 people
- At least 74% of our front-line staff have been vaccinated
- We are working hard to reach those groups that are not taking up the vaccine as much as others




Impact on waiting times for treatment



- Impact of Covid-19 on waiting times for treatment have been significant
- Nationally we are managing patients based on clinical priority
- UCLH is helping neighbouring trusts whose patients are experiencing longer waits for treatment
- There has been a significant rise in patients waiting over 52 weeks (now over 2,500)
- There have also been much longer waits for diagnostics



Impact on waiting times for cancer care




- There have been longer waits for cancer due to the pandemic.
- The impact on those waiting for longer than 62 days for treatment was much more significant in the first wave than the second, when we were able to keep many more outpatient and diagnostic services open.
- Urgent cancer surgery has continued throughout both surges.

Impact on waiting times for A&E

Type 1 performance	Q4 17-18	Q1 18-19	Q2 18-19	Q3 18-19	Q4 18-19	Q1 19-20	Q2 19-20	Q3 19-20	Q4 19-20	Q1 20-21	Q2 20-21	Q3 20-21
UCLH	86.0%	84.3%	85.0%	85.3%	81.9%	83.1%	85.0%	78.9%	73.3%	89.7%	84.9%	75.5%
London	81.0%	82.7%	82.6%	81.3%	77.3%	86.1%	77.2%	71.1%	71.8%	86.0%	86.3%	78.3%

UCLH 4-hour performance since April 2019



Strategic developments



Located on the corner of Huntley Street and Grafton Way, our new building is the Grafton Way Building. It will be home to one of only two NHS proton beam therapy (PBT) centres in the UK – the other centre is now open at The Christie in Manchester. In the floors above the PBT centre we are developing Europe's largest blood disorder treatment centre and a short stay surgical service.

Significant financial challenges

In 2020/21 following discussion with the NCL sector, the trust is forecasting a £6.2m deficit on a control total basis at year end (£1.4m adverse to plan of a £4.8m deficit).

This position is based on the following:

- An increase in the amount of annual leave owed to staff, who have been unable to take time off (-£6.2m)
- Recognition of reduced consumable spend and better than anticipated recovery of other income (+£4.8m)

Within the forecast the trust is anticipating an underspend of £11.9m on its strategic growth projects, mostly because of a delay to the Grafton Way Building. However, we are committed to returning any unspent funding to the NCL sector for re-distribution to support other providers in the system.

The trust is also forecasting additional COVID costs, £4.2m higher than plan, which are provisionally agreed to be funded by the NCL sector.